BioSpace News Archive

Actinium Pharmaceuticals, Inc. announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Inaugural Biotech CNS/Neuro Summit, taking place October 11-12, 2023 in New York City, NY.

Kineta, Inc. announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock.

Daxor Corporation today announces it has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program.

REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechnology company with a mission to redefine women’s healthcare, a non-exclusive right to use REPROCELL’s StemRNA™ Clinical Seed iPSCs.

IMIDomics Inc. today announced that it has entered into an agreement with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, aimed at accelerating the development and manufacturing of IMIDomics IMB1001.

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA ® (pembrolizumab) in Patients with Advanced Solid Tumors.

ATUM today announced an expanded partnership with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases.

Inhibikase Therapeutics, Inc. today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).

Arcturus Therapeutics Holdings Inc. announced today that ARCALIS, Arcturus’ manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been selected by the Japanese Ministry of Economy, Trade and Industry to receive additional financial support to construct a DNA template manufacturing facility along with new state-of-the-art equipment.